Published in
Wiley, Hematological Oncology, 3(38), p. 372-380, 2020
DOI: 10.1002/hon.2737
Links
Tools
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
Journal article published in 2020 by
Francesca Palandri 
,
Massimo Breccia ,
Mario Tiribelli,
Massimiliano Bonifacio,
Giulia Benevolo,
Alessandra Iurlo,
Elena M. Elli,
Gianni Binotto,
Alessia Tieghi,
Nicola Polverelli ,
Bruno Martino,
Elisabetta Abruzzese,
Micaela Bergamaschi,
Florian H. Heidel,
Francesco Cavazzini
and other authors.
,
Massimo Breccia ,
Mario Tiribelli,
Massimiliano Bonifacio,
Giulia Benevolo,
Alessandra Iurlo,
Elena M. Elli,
Gianni Binotto,
Alessia Tieghi,
Nicola Polverelli ,
Bruno Martino,
Elisabetta Abruzzese,
Micaela Bergamaschi,
Florian H. Heidel,
Francesco Cavazzini
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 